Cambridge Cognition Limited

Cambridge Cognition Limited

Cambridge Cognition is the leading global provider of cognitive assessment software for use in clinical trials, academic research and healthcare provision - advancing research, diagnosis and treatment in mental health worldwide.

Address: Turnbridge Court, Turnbridge Lane, Bottisham
Postcode: CB5 9DU
Country: United Kingdom

Cambridge Cognition is the leading provider of cognitive assessment software for academic research, healthcare provision and clinical trials. Developing global solutions to improve mental wellbeing.


Our cognitive assessment software, powered by Cantab technology, has been highly validated by over 1,200 peer-review publications.

Cantab touchscreen neuropsychological tests are used by:

  • Academic researchers in studies of cognition
  • Clinical researchers in the pharmaceutical industry, to further knowledge of cognitive function
  • Physicians to improve the monitoring, management and maintenance of cognitive health and wellbeing.

Our product ranges include:

Groundbreaking mental health wearable Cognition Kit™

Cambridge Cognition unveils the first wearable for monitoring mental health

Cambridge Cognition shows its groundbreaking mental health wearable Cognition Kit™ for the first time at the Neurotech Investing Conference in Boston this week.

7 April 2016Read in full

Cambridge Cognition ends the year on a high note

Cambridge Cognition Holdings plc, a specialist in the development and marketing of computerised tests for detection and monitoring of neuropsychological disorders, is pleased to announce that it has made significant progress with its commercial operations and expects to end the year with three new major pharmaceutical clinical trial contracts totalling US$4.5m.

24 November 2015Read in full

30 years on, CANTAB inventors herald the dawn of a new era in neuroscience

Three decades ago two emerging neuroscientists, Barbara Sahakian and Trevor Robbins from University of Cambridge, received a grant to fund their development of the Cambridge Neuropsychological Automated Test Battery or CANTAB™.

9 October 2015Read in full

Cantab Connect Alzheimer’s

New Alzheimer’s assessment product to accelerate development of treatments

Reliable cognitive measures for patients with Alzheimer's disease are essential when testing potential new drug interventions. The high attrition rate in Alzheimer’s disease clinical trials highlights the need for more sensitive analytical tools to be used throughout the drug development process.

21 May 2015Read in full

Cambridge Cognition product exceeds £1m sales in first nine months

Cambridge Cognition today announces that sales of its Cantab Connect CTIS-Abuse Liability have exceeded £1 million ($1.5 million) in its first nine months from launch.

14 April 2015Read in full

Cambridge Cognition opens US office

Cambridge Cognition has announced the opening of a US office in Salt Lake City, Utah, headed by former Baxter and Myriad executive Bill Rusconi to meet growing demand from both existing and new North American customers.

6 March 2015Read in full

Cambridge Cognition wins significant contracts

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the acceleration of safe and effective medicines in drug development, announces that it has now signed contracts with various leading pharmaceutical companies for eight human abuse and liability studies worth a total of approximately £710,000.

27 June 2014Read in full

Cognitive safety assessment products launched on Cantab Connect

Cognitive safety assessment products launched on Cantab Connect

Cambridge Cognition has announced the launch of the first two iPad-tablet products on its new cloud computing Cantab Connect platform for use in clinical trials. Rapid iPad assessment paves the way for faster and more accurate decision making on cognitive safety and abuse potential of drug treatments.

4 June 2014Read in full

Cambridge Cognition IPO raises £6.4million

Cambridge Cognition, the leading British developer of computerised neuropsychological tests, has floated on London’s Alternative Investment Market (AIM). The listing, which took place yesterday (Thurs), raised £5million. Shareholders realised a further £1.4m through the sale of existing Ordinary Shares.

19 April 2013Read in full



This is a great opportunity to join our team in Cambridge, UK. In this full-time role you will provide administration support to...

Location: Within 10 m of Cambridge
Salary: Competitive
More Info

Newsletter signup

Jobsletter signup